Base-Modified Cytidine Nucleotides for Leukemia Therapy (EP3810140A1)

Sun, 19 Apr 2026 03:22:43 +0000
Intellectual Property

The European Patent Office published patent application EP3810140A1 for Medivir Aktiebolag covering base-modified cytidine nucleotides for leukemia therapy. The application includes IPC classifications for A61K 31/506 (pyrimidine derivatives), C07D 405/04 (heterocyclic compounds), and A61P 35/02 (antineoplastic agents). The patent designates all EPO member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.